Australia's largest stock trading and investment forum Australia's #1 stock forum

MSB

Click for more information

5.70%

$1.08 mesoblast limited

Ryoncil: ODAC/FDA Meeting Discussion, page-1009

First 1009 Last

Share
Profile

Follow
anf0

1,971 Posts.

187

14/08/20

03:26

Post #: 46528904
Share

Originally posted by thisfool369: ↑

Dr Bindu George
First Speaker Afternoon Session

This session will “focus on the clinical aspects of the BLA for the treatment of pediatric patients”
“The FDA generally agrees with the applicants conclusion regarding the safety of remestemcel-L”
“Our presentation will focus on the products efficacy.”
“As discussed this morning the mechanism of action is unclear and it has been difficult to identify and characteristics that correlates with the efficacy outcome in GVHD.”
“Will rely heavily on the chemical trials to provide evidence of efficacy.”
“The efficacy data comes from GVHD study end point day 28 overall response rate.
The results from the study was pretty significant.
Dr George raised many issues with the studies.
Outlined that there were two randomized controlled trials, with data coming from trials which rolled pediatric and adult patient data together and has negative implications for results in examining efficacy for treating pediatric patients.
“We are concerned about the limitations of the study particularly the challenges that may stem from bias”

Expand

You’re not getting anywhere if the people judging you can’t even agree on the effectiveness or structure of your trial... shut the gates.

MSB Price at posting: $3.38 Sentiment: Sell Disclosure: Not Held
1 Upvote

0 Great analysis

Reply

Top Stories

SRX

Worker dies at Sierra Rutile mine

FEX

From the Floor question: "When will FEX start using rail to augment & de-risk their haulage solution?" | Fenix Resources

CC9

The USA's dominance requires a domestic lithium supply chain. Chariot stands to benefit

Chris Judd's Talk Ya Book: Tracking Life360 on a journey to the stars

AL8

From the Floor question: "What is the focus of AL8 and how is management going to attract shareholders to the registry?" | Alderan Resources

There are more pages in this discussion • 1,038 more messages in this thread...

First 1009 Last

Add MSB (ASX) to my watchlist

(20min delay)
Last $1.08		Change -0.065(5.70%)		Mkt cap ! $1.278B

Open	High	Low	Value	Volume
$1.14	$1.17	$1.07	$6.885M	6.107M

Buyers (Bids)

No.	Vol.	Price($)
10	40208	$1.08

Sellers (Offers)

Price($)	Vol.	No.
$1.08	58458	29

View Market Depth

No.	Vol.	Price($)
6	19864	1.075
15	142848	1.070
10	63167	1.065
13	147844	1.060
10	175833	1.055

Price($)	Vol.	No.
1.080	59497	26
1.085	52881	15
1.090	69696	16
1.095	31110	7
1.100	20598	4

Last trade - 14.51pm 19/06/2024 (20 minute delay)

MSB (ASX) Chart

SPONSORED BY